Eylea approved in European Union for treatment of DME

Regeneron Pharmaceuticals has received approval from the European Commission for Eylea in the treatment of visual impairment from diabetic macular edema, the company announced.Bayer Healthcare plans to launch Eylea (aflibercept) for DME in the European Union in the third quarter of 2014, according to a company news release.The U.S. Food and Drug Administration approved aflibercept for age-related macular degeneration in 2011, macular edema resulting from central retinal vein occlusion (CRVO) in 2013 and for DME in July 2014.

Full Story →